Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Cboe UK • CHF Cosmo Pharmaceuticals N.V. (COPNZ.XC) Follow Add holdings 48.53 +1.03 +(2.16%) At close: May 2 at 4:19:59 PM GMT+1 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for COPNZ.XC 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: COPNZ.XC View More All News Press Releases SEC Filings Cosmo Announces EU MDR Certification for Endovision's Cerebro, expanding its real-time AI ecosystem Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R) Cosmo Receives Negative CHMP Opinion on Winlevi(R) (clascoterone Cream 1%) in Europe and Will Appeal the Decision Cosmo Publishes Agenda of AGM 2025 Cosmo Appoints Federico Sommariva as Chief Legal Counsel Cosmo Pharmaceuticals publishes Annual Report 2024 Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and ... Cosmo Pharmaceuticals Delivers Record 2024 Results - Completes Phase III Enrollment for Androgenetic Alopecia in Males - Proposes Increased Dividend of 2.05 per share - Reinforcing Shareholder Value and Growth Momentum into 2025 Cosmo to Host Investor Day on April 9, 2025 Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio Cosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of Acne